Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

March 27, 2026 08:00 ET | Source: PRF Technologies Ltd.

PRF Technologies Provides Year-End 2025 Business Update Highlighting Strategic Progress Across Healthcare and AI-Driven Solar Platforms

LayerBio’s OcuRing™-K program and broader ocular platform strengthen PRF’s healthcare growth strategy DeepSolar advances from acquisition to early commercial deployment TEL AVIV, Israel, March 27,...
March 26, 2026 16:05 ET | Source: IRIDEX Corporation

Iridex Reports Fourth Quarter and Full Year 2025 Financial Results

MOUNTAIN VIEW, Calif., March 26, 2026 (GLOBE NEWSWIRE) -- Iridex Corporation (Nasdaq: IRIX), a worldwide leader providing innovative and versatile laser-based medical systems, delivery devices, and...
March 26, 2026 16:05 ET | Source: SpyGlass Pharma, Inc.

SpyGlass Pharma Reports Fourth Quarter and Full Year 2025 Earnings and Provides a Corporate Update

Successfully completed Initial Public Offering (IPO) in February 2026, raising $172.5 million and listing on Nasdaq.Reported positive topline 12-month data from Phase 1/2 trial of the Bimatoprost Drug...
March 26, 2026 08:00 ET | Source: MeiraGTx

MeiraGTx Announces FDA Breakthrough Therapy Designation for AAV2-hAQP1 for the Treatment of Grade 2 and Grade 3 Radiation-Induced Xerostomia (RIX) and Reports Fourth Quarter and Full Year 2025 Financial and Operational Results

FDA granted Breakthrough Therapy Designation for AAV2-hAQP1 for the treatment of Grade 2 and Grade 3 late xerostomia caused by radiotherapy for cancers of the upper aerodigestive tractMeiraGTx to hold...
March 25, 2026 09:00 ET | Source: VeonGen GmbH

VeonGen Announces Clinical Progress of VG801 Gene Therapy in Stargardt Disease, with an Oral Presentation at ARVO 2026

VG801 shows encouraging preliminary efficacy in the ongoing Phase 1/2 trial, with consistent functional improvements in best-corrected visual acuity (BCVA) and Virtual Reality Visual Test (VRVT),...
March 25, 2026 07:31 ET | Source: Vanderbilt Report and Artelo Biosciences

Artelo Biosciences Expansion into $16.3B Glaucoma Market, Via Fully Funded Study, Highlights Multi-Platform Pipeline Strength

BRISTOL, Tenn., March 25, 2026 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (NASDAQ: ARTL) is drawing increased attention following its expansion into the $16.3 billion glaucoma market through a...
March 24, 2026 12:34 ET | Source: Lucent Vision - Fountain Valley

Lucent Vision Offers SMILE Eye Surgery in Fountain Valley and Huntington Beach, California

Fountain Valley, California, March 24, 2026 (GLOBE NEWSWIRE) -- Fountain Valley, California - March 24, 2026 - - Lucent Vision is a boutique ophthalmology practice led by fellowship-trained...
March 24, 2026 09:00 ET | Source: BioAge Labs, Inc.

BioAge Labs Reports Full Year 2025 Financial Results and Provides Business Updates from the Fourth Quarter of 2025

Positive interim Phase 1 data for BGE-102, a potent, structurally novel, orally available, brain-penetrant small-molecule NLRP3 inhibitor, demonstrating potential best-in-class reductions in...
March 24, 2026 07:45 ET | Source: Ocugen

Ocugen Announces Topline 12-month Data from Phase 2 ArMaDa Clinical Trial Evaluating OCU410 Modifier Gene Therapy for Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration

Optimal dose intended for Phase 3 demonstrates statistically significant reduction in lesion growth (31%) versus control at 12 months (p< 0.05)Potential 2X treatment benefit compared to 15% and 22%...
March 23, 2026 19:05 ET | Source: Curative Biotechnology, Inc. 

Curative Biotechnology Announces Reverse Stock Split and Strategic Progress Toward OTCQB Uplisting

Strengthening Capital Structure and Advancing Clinical Development Strategy Palm Beach Gardens, FL, March 23, 2026 (GLOBE NEWSWIRE) -- Curative Biotechnology, Inc. (OTC: CUBTD) (“Curative” or the...